


Nicodicosapent

Cat. No.:	HY-17640
CAS No.:	1269181-69-2
Molecular Formula:	C ₂₈ H ₃₉ N ₃ O ₂
Molecular Weight:	449.63
Target:	Autophagy; Fatty Acid Synthase (FASN)
Pathway:	Autophagy; Metabolic Enzyme/Protease
Storage:	-20°C, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)



SOLVENT & SOLUBILITY

In Vitro	DMSO : ≥ 100 mg/mL (222.41 mM)																										
	Ethanol : 3.33 mg/mL (7.41 mM; Need ultrasonic)																										
	* "≥" means soluble, but saturation unknown.																										
	<table border="1"> <thead> <tr> <th rowspan="2">Preparing Stock Solutions</th> <th rowspan="2">Solvent Concentration</th> <th colspan="3">Mass</th> </tr> <tr> <th>1 mg</th> <th>5 mg</th> <th>10 mg</th> </tr> </thead> <tbody> <tr> <td></td> <td>1 mM</td> <td>2.2241 mL</td> <td>11.1203 mL</td> <td>22.2405 mL</td> </tr> <tr> <td></td> <td>5 mM</td> <td>0.4448 mL</td> <td>2.2241 mL</td> <td>4.4481 mL</td> </tr> <tr> <td></td> <td>10 mM</td> <td>0.2224 mL</td> <td>1.1120 mL</td> <td>2.2241 mL</td> </tr> </tbody> </table>					Preparing Stock Solutions	Solvent Concentration	Mass			1 mg	5 mg	10 mg		1 mM	2.2241 mL	11.1203 mL	22.2405 mL		5 mM	0.4448 mL	2.2241 mL	4.4481 mL		10 mM	0.2224 mL	1.1120 mL
Preparing Stock Solutions	Solvent Concentration	Mass																									
		1 mg	5 mg	10 mg																							
	1 mM	2.2241 mL	11.1203 mL	22.2405 mL																							
	5 mM	0.4448 mL	2.2241 mL	4.4481 mL																							
	10 mM	0.2224 mL	1.1120 mL	2.2241 mL																							
Please refer to the solubility information to select the appropriate solvent.																											
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 3.75 mg/mL (8.34 mM); Clear solution																										

BIOLOGICAL ACTIVITY

Description	Nicodicosapent is a fatty acid niacin conjugate that is also an inhibitor of the sterol regulatory element binding protein (SREBP), a key regulator of cholesterol metabolism proteins such as PCSK9, HMG-CoA reductase, ATP citrate lyase, and NPC1L1.
In Vitro	Nicodicosapent decreases the production of mature SREBP-2 protein in HepG2 cells, but does not interact with the GPR109A receptor. Nicodicosapent shows a synergistic inhibition on secreted PCSK9 and has an IC ₅₀ value of 17 μM. Nicodicosapent significantly inhibits ApoB secretion in a dose-dependent manner with IC ₅₀ of 27 μM. Nicodicosapent results in a time-dependent hydrolysis in HepG2 cells ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Nicodicosapent (100 mg/kg po) produces high plasma levels of nicotinuric acid in the plasma. ApoE*3-Leiden mice treated with Nicodicosapent show a significant reduction in PCSK9 levels, LDL particles including VLDL and LDL cholesterol, as well

as plasma triglycerides^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Animal Administration ^[1]

Male Sprague-Dawley rats (n=4/treatment group) are administered with a single oral dose of either niacin (30 mg/kg) or Nicodicosapent (100 mg/kg). Compounds are formulated as an aqueous emulsion using Tween, Peceol, PEG400, and tocopherol. Nicodicosapent (170 mg) is formulated in 2.38 g of the oil mixture containing 40% Tween, 50% Peceol, 10% PEG400, and 0.2% tocopherol. The concentration of 5 in oil is 66 mg/g of oil. For oral dosing, this oil formulation is then diluted with 14.25 mL of water to form a 10 mg/mL drug emulsion and dosed as an oral gavage. Collection time points are 5, 15, and 30 min 1, 2, 4, 6, and 8 h postdose. Blood samples are collected via saphenous vein and placed in tubes containing paraoxon (10 µL of a 200 µM solution in DMSO) and stored on an ice block until centrifuged at 8000 rpm for 6 min at 2-8°C. The resulting plasma is kept frozen at -80°C until analysis. Nicodicosapent, nicotinic acid, and nicotinuric acid standard curves are generated to allow for quantitative analysis of plasma samples. Standard curves are generated by adding 10 µL of a given compound in methanol (50 µg/mL) to 50 µL of blank plasma in a 96-well microplate, resulting in the following final concentration range: 8333, 2083, 521, 130.2, 32.5, 8.1, 2.0, and 0.5 ng/mL. Then 300 µL of acetonitrile containing 100 ng/mL of an internal standard is added to each sample. The 96-well microplate is vortexed for 30 s and is then centrifuged for 45 min at 2300 g. Then 100 µL of supernatant is transferred from each sample to an empty 96-well microplate for analysis by LC/MS/MS. The instrument used is an Agilent liquid chromatograph equipped with a binary pump (1200 series), an autosampler (1200 series), and a degasser (1200 series). Mass spectrometric analysis is performed using an Agilent 6410 triple quadrupole with an ESI interface. The data acquisition and quantitation is done with Agilent Masshunter software. The column used is a Phenomenex Gemini C6 Phenyl 110A 50 mm×4.6 mm, 1.8 µm. The following mobile phase gradient is used (water = solvent A; methanol = solvent B): 0.01 min=45%A/55%B; 0.5 min=45%A/55%B; 1 min=5%A/95%B; 3.5 min=5%A/95%B; 3.51 min=45%A/55%B; 4 min=45%A/55%B.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Vu CB, et al. Synthesis and Characterization of Fatty Acid Conjugates of Niacin and Salicylic Acid. J Med Chem. 2016 Feb 11;59(3):1217-31.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA